These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
338 related articles for article (PubMed ID: 27464720)
1. Solving the Blood-Brain Barrier Challenge for the Effective Treatment of HIV Replication in the Central Nervous System. Bertrand L; Nair M; Toborek M Curr Pharm Des; 2016; 22(35):5477-5486. PubMed ID: 27464720 [TBL] [Abstract][Full Text] [Related]
2. An Elvitegravir Nanoformulation Crosses the Blood-Brain Barrier and Suppresses HIV-1 Replication in Microglia. Gong Y; Zhi K; Nagesh PKB; Sinha N; Chowdhury P; Chen H; Gorantla S; Yallapu MM; Kumar S Viruses; 2020 May; 12(5):. PubMed ID: 32443728 [TBL] [Abstract][Full Text] [Related]
3. Specific increase in MDR1 mediated drug-efflux in human brain endothelial cells following co-exposure to HIV-1 and saquinavir. Roy U; Bulot C; Honer zu Bentrup K; Mondal D PLoS One; 2013; 8(10):e75374. PubMed ID: 24098380 [TBL] [Abstract][Full Text] [Related]
4. Nanoformulated Antiretrovirals for Penetration of the Central Nervous System: State of the Art. Fiandra L; Capetti A; Sorrentino L; Corsi F J Neuroimmune Pharmacol; 2017 Mar; 12(1):17-30. PubMed ID: 27832401 [TBL] [Abstract][Full Text] [Related]
5. The far-reaching HAND of cART: cART effects on astrocytes. Gonzalez H; Podany A; Al-Harthi L; Wallace J J Neuroimmune Pharmacol; 2021 Mar; 16(1):144-158. PubMed ID: 32147775 [TBL] [Abstract][Full Text] [Related]
6. Treating HIV Infection in the Central Nervous System. Calcagno A; Di Perri G; Bonora S Drugs; 2017 Feb; 77(2):145-157. PubMed ID: 28070871 [TBL] [Abstract][Full Text] [Related]
7. Novel Central Nervous System (CNS)-Targeting Protease Inhibitors for Drug-Resistant HIV Infection and HIV-Associated CNS Complications. Amano M; Salcedo-Gómez PM; Yedidi RS; Zhao R; Hayashi H; Hasegawa K; Nakamura T; Martyr CD; Ghosh AK; Mitsuya H Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31061155 [TBL] [Abstract][Full Text] [Related]
8. Enhancing the delivery of anti retroviral drug "Saquinavir" across the blood brain barrier using nanoparticles. Mahajan SD; Roy I; Xu G; Yong KT; Ding H; Aalinkeel R; Reynolds J; Sykes D; Nair BB; Lin EY; Prasad PN; Schwartz SA Curr HIV Res; 2010 Jul; 8(5):396-404. PubMed ID: 20426757 [TBL] [Abstract][Full Text] [Related]
9. A Modified P1 Moiety Enhances In Vitro Antiviral Activity against Various Multidrug-Resistant HIV-1 Variants and In Vitro Central Nervous System Penetration Properties of a Novel Nonpeptidic Protease Inhibitor, GRL-10413. Amano M; Salcedo-Gómez PM; Zhao R; Yedidi RS; Das D; Bulut H; Delino NS; Sheri VR; Ghosh AK; Mitsuya H Antimicrob Agents Chemother; 2016 Dec; 60(12):7046-7059. PubMed ID: 27620483 [TBL] [Abstract][Full Text] [Related]
10. Mechanisms of HIV entry into the CNS: increased sensitivity of HIV infected CD14+CD16+ monocytes to CCL2 and key roles of CCR2, JAM-A, and ALCAM in diapedesis. Williams DW; Calderon TM; Lopez L; Carvallo-Torres L; Gaskill PJ; Eugenin EA; Morgello S; Berman JW PLoS One; 2013; 8(7):e69270. PubMed ID: 23922698 [TBL] [Abstract][Full Text] [Related]
11. Viral Infection of the Central Nervous System and Neuroinflammation Precede Blood-Brain Barrier Disruption during Japanese Encephalitis Virus Infection. Li F; Wang Y; Yu L; Cao S; Wang K; Yuan J; Wang C; Wang K; Cui M; Fu ZF J Virol; 2015 May; 89(10):5602-14. PubMed ID: 25762733 [TBL] [Abstract][Full Text] [Related]
12. Methamphetamine toxicity and its implications during HIV-1 infection. Silverstein PS; Shah A; Gupte R; Liu X; Piepho RW; Kumar S; Kumar A J Neurovirol; 2011 Oct; 17(5):401-15. PubMed ID: 21786077 [TBL] [Abstract][Full Text] [Related]
13. Novel elvitegravir nanoformulation for drug delivery across the blood-brain barrier to achieve HIV-1 suppression in the CNS macrophages. Gong Y; Chowdhury P; Nagesh PKB; Rahman MA; Zhi K; Yallapu MM; Kumar S Sci Rep; 2020 Mar; 10(1):3835. PubMed ID: 32123217 [TBL] [Abstract][Full Text] [Related]
14. Compartmentalization, Viral Evolution, and Viral Latency of HIV in the CNS. Bednar MM; Sturdevant CB; Tompkins LA; Arrildt KT; Dukhovlinova E; Kincer LP; Swanstrom R Curr HIV/AIDS Rep; 2015 Jun; 12(2):262-71. PubMed ID: 25914150 [TBL] [Abstract][Full Text] [Related]
15. HIV and viral protein effects on the blood brain barrier. McRae M Tissue Barriers; 2016; 4(1):e1143543. PubMed ID: 27141423 [TBL] [Abstract][Full Text] [Related]
16. Beneficial and Adverse Effects of cART Affect Neurocognitive Function in HIV-1 Infection: Balancing Viral Suppression against Neuronal Stress and Injury. Yuan NY; Kaul M J Neuroimmune Pharmacol; 2021 Mar; 16(1):90-112. PubMed ID: 31385157 [TBL] [Abstract][Full Text] [Related]
17. The interferon-induced expression of APOBEC3G in human blood-brain barrier exerts a potent intrinsic immunity to block HIV-1 entry to central nervous system. Argyris EG; Acheampong E; Wang F; Huang J; Chen K; Mukhtar M; Zhang H Virology; 2007 Oct; 367(2):440-51. PubMed ID: 17631933 [TBL] [Abstract][Full Text] [Related]
18. The Janus kinase inhibitor ruxolitinib reduces HIV replication in human macrophages and ameliorates HIV encephalitis in a murine model. Haile WB; Gavegnano C; Tao S; Jiang Y; Schinazi RF; Tyor WR Neurobiol Dis; 2016 Aug; 92(Pt B):137-43. PubMed ID: 26851503 [TBL] [Abstract][Full Text] [Related]
19. HIV pharmacology: barriers to the eradication of HIV from the CNS. McGee B; Smith N; Aweeka F HIV Clin Trials; 2006; 7(3):142-53. PubMed ID: 16880170 [TBL] [Abstract][Full Text] [Related]
20. The blood brain barrier in HIV infection. Berger JR; Avison M Front Biosci; 2004 Sep; 9():2680-5. PubMed ID: 15358591 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]